April 27, 2023
Meiji Seika Pharma said on April 26 that it has kicked off a global PIII clinical trial for nacubactam, a novel β-lactamase inhibitor expected to become a potential weapon against antimicrobial resistance (AMR). The new trial for the drug, also...read more